August 3, 2026 · Annals of internal medicine · DOI: 10.7326/ANNALS-26-02527-JC

In older adults, mRNA-1010 vs. a licensed standard-dose influenza vaccine reduced influenza A- or B-related ILI at a median 181 d

Listen to this summary

The authors investigate the efficacy of mRNA-1010 compared to a licensed standard-dose influenza vaccine in reducing influenza A- or B-related influenza-like illness (ILI) in older adults. Their findings indicate that mRNA-1010 demonstrated a significant reduction in ILI over a median follow-up period of 181 days. This study aims to assess the potential advantages of mRNA technology in influenza vaccination for older populations.

Victor Chen, Aaron E Glatt, ACP Journal Club Editorial Team at McMaster University

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play